Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 227

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 227
---
 condition. The market price of our Common Stock or Tradeable Warrants may fluctuate as a result
of a number of factors, some of which are beyond our control, including, but not limited to:

    ●
    actual
    or anticipated variations in our and our competitors’ results of operations and financial condition;

    ●
    market
    acceptance of our diagnostic tests and therapeutic products;

    ●
    the
    mix of products that we sell and related services that we provide;

    ●
    changes
    in earnings estimates or recommendations by securities analysts, if our Common Stock is covered by analysts;

    ●
    development
    of technological innovations or new competitive diagnostic tests or therapeutic products by others;

    ●
    announcements
    of technological innovations or new diagnostic tests or therapeutic products by us;

    ●
    our
    failure to achieve a publicly announced milestone;

    ●
    delays
    between our expenditures to develop and market new or enhanced diagnostic tests or therapeutic products and the generation of sales
    from those diagnostic tests and therapeutic products;

    ●
    developments
    concerning intellectual property rights, including our involvement in litigation;

    ●
    regulatory
    developments and the decisions of regulatory authorities as to the approval or rejection of new or modified diagnostic tests or therapeutic
    products;

    ●
    changes
    in the amounts that we spend to develop, acquire, or license new diagnostic tests or therapeutic products, technologies, or businesses;

    ●
    changes
    in our expenditures to promote our diagnostic tests or therapeutic products;

    ●
    our
    sale or proposed sale, or the sale by our significant shareholders, of our Common Stock or other securities in the future;

    ●
    changes
    in key personnel;

    ●
    success
    or failure of our research and development projects or those of our competitors;

    ●
    the
    trading volume of our Common Stock; and

    ●
    general
    economic and market conditions and other factors, including factors unrelated to our operating performance.

These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our Common Stock or Tradeable
Warrants and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public
company shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could
impose a substantial cost upon us and divert the resources and attention of our management from our business